Alliance for Clinical Trials in Oncology
- Country
- πΊπΈUnited States
- Ownership
- Private
- Established
- 2011-01-01
- Employees
- 251
- Market Cap
- -
Trying to Find the Correct Length of Treatment with Immune Checkpoint Therapy
- Conditions
- Locally Advanced Urothelial CarcinomaLocally Advanced Urethral Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial CarcinomaMetastatic Urethral Urothelial CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis Urothelial CarcinomaMetastatic Ureter Urothelial CarcinomaMetastatic Urothelial CarcinomaLocally Advanced Bladder Urothelial Carcinoma
- Interventions
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 3
- Registration Number
- NCT04637594
- Locations
- πΊπΈ
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
πΊπΈAnchorage Radiation Therapy Center, Anchorage, Alaska, United States
πΊπΈAlaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer
- Conditions
- Prostate Carcinoma
- Interventions
- Drug: Placebo AdministrationOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 88
- Registration Number
- NCT04600336
- Locations
- πΊπΈ
Arizona Breast Cancer Specialists-Gilbert, Gilbert, Arizona, United States
πΊπΈArizona Center for Cancer Care-Peoria, Peoria, Arizona, United States
πΊπΈCancer Center at Saint Joseph's, Phoenix, Arizona, United States
Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions
- Conditions
- Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage 0 Breast Cancer AJCC v8
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 543
- Registration Number
- NCT04549571
- Locations
- πΊπΈ
SSM Health Good Samaritan, Mount Vernon, Illinois, United States
πΊπΈAscension Borgess Hospital, Kalamazoo, Michigan, United States
πΊπΈKaiser Permanente-Vallejo, Vallejo, California, United States
Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer
- Conditions
- Recurrent Lung AdenocarcinomaStage IV Lung Cancer AJCC v8Metastatic Lung AdenocarcinomaMetastatic Lung Non-Small Cell CarcinomaStage IVB Lung Cancer AJCC v8Recurrent Lung Non-Small Cell CarcinomaStage IVA Lung Cancer AJCC v8
- Interventions
- Other: Comprehensive Geriatric AssessmentOther: Questionnaire AdministrationOther: Quality-of-Life Assessment
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 101
- Registration Number
- NCT04533451
- Locations
- πΊπΈ
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
πΊπΈAnchorage Radiation Therapy Center, Anchorage, Alaska, United States
πΊπΈAlaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
- Conditions
- Anatomic Stage IA Breast Cancer AJCC V8Anatomic Stage II Breast Cancer AJCC V8Anatomic Stage IIA Breast Cancer AJCC V8Anatomic Stage IIB Breast Cancer AJCC V8Anatomic Stage III Breast Cancer AJCC V8Anatomic Stage IIIA Breast Cancer AJCC V8Anatomic Stage IIIB Breast Cancer AJCC V8Anatomic Stage IIIC Breast Cancer AJCC V8HER2 Positive Breast CarcinomaInvasive Breast Carcinoma
- Interventions
- Drug: Placebo AdministrationOther: Questionnaire AdministrationOther: Quality-of-Life Assessment
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1031
- Registration Number
- NCT04457596
- Locations
- πΊπΈ
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
πΊπΈThomas Hospital, Fairhope, Alabama, United States
πΊπΈMobile Infirmary Medical Center, Mobile, Alabama, United States
A Clinical Study Evaluating the Benefit of Adding Rucaparib to Enzalutamide for Men with Metastatic Prostate Cancer That Has Become Resistant to Testosterone-Deprivation Therapy
- Conditions
- Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IV Prostate Cancer AJCC V8Stage IVA Prostate Cancer AJCC V8Stage IVB Prostate Cancer AJCC V8
- Interventions
- Drug: PlaceboOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 61
- Registration Number
- NCT04455750
- Locations
- πΊπΈ
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
πΊπΈAnchorage Radiation Therapy Center, Anchorage, Alaska, United States
πΊπΈAlaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Invasive Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Prognostic Stage I Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8HER2 Negative Breast CarcinomaHormone Receptor Positive Breast CarcinomaPrognostic Stage II Breast Cancer AJCC v8
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1180
- Registration Number
- NCT04379570
- Locations
- πΊπΈ
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
πΊπΈFairbanks Memorial Hospital, Fairbanks, Alaska, United States
πΊπΈArizona Center for Cancer Care - Gilbert, Gilbert, Arizona, United States
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
- Conditions
- Pancreatic Adenosquamous CarcinomaResectable Pancreatic AdenocarcinomaPancreatic Cancer
- Interventions
- Procedure: ResectionOther: Questionnaire Administration
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 352
- Registration Number
- NCT04340141
- Locations
- πΊπΈ
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
πΊπΈThomas Hospital, Fairhope, Alabama, United States
πΊπΈMobile Infirmary Medical Center, Mobile, Alabama, United States
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
- Conditions
- Malignancy
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 240
- Registration Number
- NCT04242095
- Locations
- πΊπΈ
Saint Joseph's Medical Center, Stockton, California, United States
πΊπΈCarle BroMenn Medical Center, Normal, Illinois, United States
πΊπΈCarle Cancer Institute Normal, Normal, Illinois, United States
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients with Stage II-III Colorectal Cancer
- Conditions
- Stage II Colorectal Cancer AJCC V8Stage III Colorectal Cancer AJCC V8
- Interventions
- Other: Quality-of-Life AssessmentOther: PlaceboOther: Questionnaire Administration
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 220
- Registration Number
- NCT04137107
- Locations
- πΊπΈ
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
πΊπΈUniversity of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
πΊπΈAnchorage Associates in Radiation Medicine, Anchorage, Alaska, United States